What is it about?
In Acute Kidney Injury(AKi) the kidney function changes quickly. Conventional methods of estimating GFR are not applicable in this context. Using KeGFR provides significantly different dosing for important medications compared to these methods.
Featured Image
Why is it important?
Dosing medications safely during AKI has been a challenge as conventional GFR estimating methods do not reflect the underlying changes in the kidney function. Using KeGFR may provide safer and more effective dosing recommendations for medications excreted by the kidney.
Perspectives
This is a pilot study paving the way for prospective studies using KeGFR in tandem with Cockroft Gault eCrCl to dose medications excreted by the kidney. Therapeutic drug monitoring might help to show if drug levels are in the therapeutic range when KeGFR is used. KeGFR is intuitive and easy to adopt in the electronic medical records system. This study was fun to do and we hope this leads to better outcomes for our patients with AKI.
Associate Prof Manohar Bairy
Tan Tock Seng Hospital
Read the Original
This page is a summary of: Using Kinetic eGFR for Drug Dosing in AKI: Concordance between Kinetic eGFR, Cockroft-Gault Estimated Creatinine Clearance, and MDRD eGFR for Drug Dosing Categories in a Pilot Study Cohort, May 2020, Karger Publishers,
DOI: 10.1159/000507260.
You can read the full text:
Contributors
The following have contributed to this page
